Praxis Precision Medicines, Inc.(PRAX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PRAX Praxis Precision Medicines, Inc.

Closed 08-26 16:00:00 EDT

377.37

+9.35

+2.54%

盘后377.37

+0.000.00%

19:30 EDT

High383.30	Low362.79	Vol480.53K
Open368.45	D1 Closing368.02	Amplitude5.57%
Mkt Cap10.51B	Tradable Cap9.09B	Total Shares27.85M
T/O180.71M	T/O Rate2.00%	Tradable Shares24.08M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PRAX","market":"US","secType":"STK","nameCN":"Praxis Precision Medicines, Inc.","latestPrice":377.37,"timestamp":1787774400000,"preClose":368.02,"halted":0,"volume":480526,"hourTrading":{"tag":"盘后","latestPrice":377.37,"preClose":377.37,"latestTime":"19:30 EDT","volume":2611,"amount":985513.09,"timestamp":1787787003520,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.025406227922395584,"floatShares":24076500,"shares":27850833,"eps":-12.863398,"marketStatus":"Closed","change":9.35,"latestTime":"08-26 16:00:00 EDT","open":368.45,"high":383.3,"low":362.79,"amount":180709058.2426,"amplitude":0.055731,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-12.863398,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787817600000},"marketStatusCode":5,"adr":0,"listingDate":1602820800000,"exchange":"NASDAQ","adjPreClose":368.02,"preHourTrading":{"tag":"盘前","latestPrice":374.99,"preClose":368.02,"latestTime":"09:24 EDT","volume":15,"amount":5562.2301,"timestamp":1787750697452,"change":6.97,"changeRate":0.018939,"amplitude":0.020773},"postHourTrading":{"tag":"盘后","latestPrice":377.37,"preClose":377.37,"latestTime":"19:30 EDT","volume":2611,"amount":985513.09,"timestamp":1787787003520,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.270484,"impliedVol":0.6347,"impliedVolPercentile":0.1235},"requestUrl":"/m/hq/s/PRAX/tweets","defaultTab":"tweets","newsList":[{"id":"1166217448","title":"Movement Alert｜Praxis Precision Medicines, Inc. Rises 5.15% in Regular Trading, Trading at $389.76","url":"https://stock-news.laohu8.com/highlight/detail?id=1166217448","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166217448?lang=en_us&edition=fundamental","pubTime":"2026-08-20 03:32","pubTimestamp":1787167942,"startTime":"0","endTime":"0","summary":"On August 20, Praxis Precision Medicines, Inc. rose 5.15% in regular trading, trading at $389.76/share, with Turnover of $114 million.Within the Biotechnology sector where Praxis Precision Medicines,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660043669","title":"Praxis Precision Medicines Could Be Approaching 'Perfect Trifecta,' Oppenheimer Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2660043669","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660043669?lang=en_us&edition=fundamental","pubTime":"2026-08-17 23:21","pubTimestamp":1786980102,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines (PRAX) could be approaching an unprecedented regulatory stretch, with four potential approvals across three drugs within roughly 12 months, a potential \"perfect trifecta,\" O","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BJJMRZ35.SGD","IE0009355771.USD","IBRN","IE00B4R5TH58.HKD","LU0320765992.SGD","IE00BFTCPJ56.SGD","BK4139","IE0002141913.USD","IE00B2B36J28.USD","OPY","BK4127","LU0889565916.HKD","LU0109394709.USD","IE00BJT1NW94.SGD","PRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660484118","title":"Praxis Precision Medicines, Inc. : Raymond James Raises Target Price to $945 from $765","url":"https://stock-news.laohu8.com/highlight/detail?id=2660484118","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660484118?lang=en_us&edition=fundamental","pubTime":"2026-08-17 19:10","pubTimestamp":1786965021,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nFWN44E0K1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE0002141913.USD","IBRN","PRAX","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","LU0889565916.HKD","IE0009355771.USD","IE00BJJMRZ35.SGD","LU0109394709.USD","LU0320765992.SGD","BK4139","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657641228","title":"Praxis Precision Med is Maintained at Equal-Weight by Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2657641228","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657641228?lang=en_us&edition=fundamental","pubTime":"2026-08-07 22:07","pubTimestamp":1786111620,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PRAX/analyst-ratings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3581.USD","LU0889565916.HKD","BK4504","LU1814569148.SGD","LU0211328371.USD","LU0128525689.USD","LU0162691827.USD","LU2361044949.HKD","IE0002141913.USD","LU1894683264.USD","LU2236285917.USD","IE0009355771.USD","IE00BJJMRZ35.SGD","LU0971096721.USD","LU0211327993.USD","BK4559","LU0072461881.USD","IE00B19Z3B42.SGD","PRAX","BK4139","BK4585","IBRN","LU0149725797.USD","LU0640476718.USD","LU1280957306.USD","LU0310800965.SGD","LU0742534661.SGD","KBWB","LU0048573561.USD","LU0256863811.USD","LU0868494617.USD","LU1074936037.SGD","LU2461242641.AUD","LU1267930227.SGD","LU0251142724.SGD","BK4582","LU0320765489.SGD","FTXO","IE00BFTCPJ56.SGD","IYF","IE0002270589.USD","LU1506573853.SGD","IE00BJT1NW94.SGD","BK4207","LU1201861249.SGD","LU0320765992.SGD","LU0417517546.SGD","LU0868494708.USD","TFNS","PGF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657645754","title":"Analysts Offer Insights on Healthcare Companies: Viatris (VTRS), Immunocore Holdings (IMCR) and Praxis Precision Medicines (PRAX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657645754","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657645754?lang=en_us&edition=fundamental","pubTime":"2026-08-07 20:40","pubTimestamp":1786106428,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Viatris (VTRS), Immunocore Holdings (IMCR) and Pra...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-viatris-vtrs-immunocore-holdings-imcr-and-praxis-precision-medicines-prax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-viatris-vtrs-immunocore-holdings-imcr-and-praxis-precision-medicines-prax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4583","IE00B2B36J28.USD","IMCR","PRAX","BK4585","IE00BFTCPJ56.SGD","BK4137","LU0109394709.USD","IBRN","IE0002141913.USD","IE00BJJMRZ35.SGD","IE0009355771.USD","LABU","VTRS","LU0320765992.SGD","LU0029874061.USD","HCSG","IE00B4R5TH58.HKD","BK4007","BK4588","LU0889565916.HKD","XBI","BK4139","LU2087621335.USD","IE00BJT1NW94.SGD","XLV","BK4505","BK4581","LU1839511570.USD","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657643664","title":"Praxis Precision price target raised to $514 from $400 at Baird","url":"https://stock-news.laohu8.com/highlight/detail?id=2657643664","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657643664?lang=en_us&edition=fundamental","pubTime":"2026-08-07 20:01","pubTimestamp":1786104075,"startTime":"0","endTime":"0","summary":"Baird raised the firm’s price target on Praxis Precision (PRAX) to $514 from $400 and keeps an Outperform rating on the shares. The firm updated it...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/praxis-precision-price-target-raised-to-514-from-400-at-baird-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/praxis-precision-price-target-raised-to-514-from-400-at-baird-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0002141913.USD","IE00BFTCPJ56.SGD","IBRN","BK4139","LU0109394709.USD","IE00BJT1NW94.SGD","PRAX","IE00BJJMRZ35.SGD","LU0320765992.SGD","LU0889565916.HKD","IE00B2B36J28.USD","IE0009355771.USD","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657648808","title":"Praxis Precision Medicines, Inc. : Deutsche Bank Raises Target Price to $475 from $374","url":"https://stock-news.laohu8.com/highlight/detail?id=2657648808","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657648808?lang=en_us&edition=fundamental","pubTime":"2026-08-07 19:26","pubTimestamp":1786101999,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nFWN44419L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE0002141913.USD","LU0109394709.USD","IE00B2B36J28.USD","LU0320765992.SGD","PRAX","IBRN","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","LU0889565916.HKD","BK4139","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657650957","title":"Definium Therapeutics Q2 Net Loss Widens on Higher Warrant Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2657650957","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657650957?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:17","pubTimestamp":1786047436,"startTime":"0","endTime":"0","summary":"Definium Therapeutics Q2 net loss widens on higher warrant costsOverviewUS biopharma firm's Q2 net loss widens, driven by higher warrant liabilities and expensesCompany raised $805 mln in public offer","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431D2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","LU0320765992.SGD","IE00B2B36J28.USD","LU0889565916.HKD","IE00BJT1NW94.SGD","IE0002141913.USD","IE00BFTCPJ56.SGD","PRAX","IE00BJJMRZ35.SGD","VTVT","BK4007","IE0009355771.USD","IE00B4R5TH58.HKD","IBRN","DTIL","BK4139","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657650887","title":"Canada's Xenon Pharma Q2 Net Loss Widens on Higher Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2657650887","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657650887?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:14","pubTimestamp":1786047240,"startTime":"0","endTime":"0","summary":"Canada's Xenon Pharma Q2 net loss widens on higher expensesOverviewCanada neuroscience drug developer's Q2 net loss widened and missed analyst expectationsHigher R&D and administrative costs drove the","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431DZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","LU0154245756.USD","LU0889565916.HKD","IE00B4R5TH58.HKD","BK4007","IE0002141913.USD","LU2065170008.USD","IE0009355771.USD","XENE","IE00BJJMRZ35.SGD","LU0109394709.USD","PRAX","BK4139","SBIO","IBRN","GHRS","LU0154245673.USD","LU2324357040.USD","LU2065169927.USD","IMRX","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","BK4539","IE00BJT1NW94.SGD","LU2065171402.SGD","LU0320765992.SGD","LU2065171311.SGD","LU0823416689.USD","PSIL","NBIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657651400","title":"Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA), Privia Health Group (PRVA) and Praxis Precision Medicines (PRAX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657651400","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657651400?lang=en_us&edition=fundamental","pubTime":"2026-08-07 01:50","pubTimestamp":1786038610,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Tenaya Therapeutics (TNYA), Privia Health Group (PRV...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-tenaya-therapeutics-tnya-privia-health-group-prva-and-praxis-precision-medicines-prax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-tenaya-therapeutics-tnya-privia-health-group-prva-and-praxis-precision-medicines-prax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LU0889565916.HKD","IBRN","BK4581","LU0128526141.USD","LU0320765992.SGD","PRVA","IE0009355771.USD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","LABU","TNYA","IE0002141913.USD","BK4139","BK4588","BK4137","LU0109394709.USD","IE00B4R5TH58.HKD","XBI","PRAX","IE00B2B36J28.USD","BK4196","LU0029874061.USD","HCSG","XLV","BK4539","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657265655","title":"Wedbush Adjusts PT on Praxis Precision Medicines to $188 From $162, Maintains Underperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2657265655","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657265655?lang=en_us&edition=fundamental","pubTime":"2026-08-06 23:58","pubTimestamp":1786031892,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines (PRAX) has an average rating of buy and mean price target of $604.83, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105825563","title":"Movement Alert｜Praxis Precision Medicines, Inc. Rises 16.43% in Regular Trading, Q2 Earnings and Pipeline Catalysts Drive Surge","url":"https://stock-news.laohu8.com/highlight/detail?id=1105825563","media":"Market Focus","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105825563?lang=en_us&edition=fundamental","pubTime":"2026-08-06 23:15","pubTimestamp":1786029313,"startTime":"0","endTime":"0","summary":"On August 6, Praxis Precision Medicines, Inc. rose 16.43% in regular trading, trading at $371.86/share, with turnover of $176 million.The surge was driven by the company releasing its second-quarter...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657163708","title":"Praxis Precision Medicines, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657163708","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657163708?lang=en_us&edition=fundamental","pubTime":"2026-08-06 22:07","pubTimestamp":1786025274,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines, Inc. reports results for the quarter ended June 30 - Earnings SummaryPraxis Precision Medicines, Inc.PRAX.OQreported a quarterly adjusted loss of $2.87 per share for the qu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N44326M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","PRAX","IBRN","IE00B2B36J28.USD","IE00B4R5TH58.HKD","LU0320765992.SGD","BK4139","IE0009355771.USD","IE00BFTCPJ56.SGD","LU0109394709.USD","IE0002141913.USD","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136842568","title":"Stock Track | Praxis Precision Medicines Soars 14.56% Intraday on Q2 Earnings Beat and Positive FDA Pipeline Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=1136842568","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136842568?lang=en_us&edition=fundamental","pubTime":"2026-08-06 21:44","pubTimestamp":1786023894,"startTime":"0","endTime":"0","summary":"Shares of Praxis Precision Medicines, Inc. (PRAX) surged 14.56% during intraday trading on Thursday, driven by better-than-expected second-quarter financial results and encouraging regulatory...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["PRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657111634","title":"Praxis Q2 2026 results: $1.4 billion liquidity supports runway into 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2657111634","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657111634?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:53","pubTimestamp":1786020784,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines’ Q2 2026 results showed a net loss of $83.7 million, up from $71.1 million a year earlier, while diluted loss per share narrowed to $2.87 from $3.31 because the weighted-average share count increased. R&D expense rose to $69.4 million and G&A expense more than doubled to $27.5 million. Cash, cash equivalents and marketable securities totaled approximately $1.4 billion at June 30, supporting operations into 2028 as Praxis prepares for regulatory decisions on relutrigine and ulixacaltamide and advances key epilepsy studies.","market":"other","thumbnail":"https://resource.tradingkey.com/cdn/images/article/news/stock10.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cdn/images/article/news/stock10.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/earnings/262084149-tradingkey","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","IE0002141913.USD","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","LABU","LU0889565916.HKD","PRAX","IBRN","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","BK4585","IE00B4R5TH58.HKD","LU0320765992.SGD","BK4139","BK4588","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657696631","title":"Praxis Precision Medicines Posts Investor Deck Highlighting Late-Stage CNS Pipeline, Upcoming PDUFA Dates","url":"https://stock-news.laohu8.com/highlight/detail?id=2657696631","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657696631?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:37","pubTimestamp":1786019853,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines posts investor deck highlighting late-stage CNS pipeline, upcoming PDUFA datesPraxis Precision Medicines highlighted four late-stage CNS programs, citing portfolio peak sale","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL9lM7CK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","IE0009355771.USD","IE00BFTCPJ56.SGD","LU0889565916.HKD","IE0002141913.USD","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","LU0320765992.SGD","BK4139","IBRN","PRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126480203","title":"Stock Track | Praxis Precision Medicines Soars 5.88% in Pre-market on Q2 Earnings Beat and Upbeat Pipeline Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=1126480203","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126480203?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:14","pubTimestamp":1786018473,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines, Inc. (PRAX) surged 5.88% in pre-market trading after the company reported second-quarter financial results that exceeded analyst expectations and provided a positive...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["PRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657395516","title":"Praxis Precision Q2 Net Loss Widens on Higher Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2657395516","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657395516?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:12","pubTimestamp":1786018371,"startTime":"0","endTime":"0","summary":"Praxis Precision Q2 net loss widens on higher expensesOverviewUS CNS drug developer's Q2 net loss widened yr/yr on higher operating expensesCompany ended Q2 with $1.4 bln in cash and investments, fund","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4430NP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","IE00BJT1NW94.SGD","LU0889565916.HKD","BK4139","BK4007","IE00BJJMRZ35.SGD","LU0109394709.USD","HRMY","PSIL","IBRN","IE00B2B36J28.USD","IE0002141913.USD","IE00BFTCPJ56.SGD","LU0320765992.SGD","GHRS","VNDA","BK4539","IE00B4R5TH58.HKD","PRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657398376","title":"Praxis Precision Net Loss Widens 17.7% to $83.72 Million in Q2 FY26","url":"https://stock-news.laohu8.com/highlight/detail?id=2657398376","media":"Reuters","labels":["corporation","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657398376?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:08","pubTimestamp":1786018121,"startTime":"0","endTime":"0","summary":"Praxis Precision net loss widens 17.7% to $83.72 million in Q2 FY26Praxis Precision Medicines posted a Q2 GAAP net loss of USD 83.7 million, widening from USD 71.1 million a year earlier.R&D expenses rose 10.16% to USD 69.4 million, driven by higher Solidus spending and personnel costs, partly offset by lower Cerebrum expenses.G&A costs more than doubled to USD 27.5 million, on higher professional fees and personnel-related expenses.Cash, cash equivalents and marketable securities totaled USD 1.4 billion at June 30, extending the expected operating runway into 2028.FDA mid-cycle reviews flagged no major safety or efficacy issues for ulixacaltamide  or relutrigine .Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Praxis Precision Medicine","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL9blbZs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","IE00BJJMRZ35.SGD","LU0889565916.HKD","IE00BFTCPJ56.SGD","IBRN","IE00BJT1NW94.SGD","BK4139","IE00B2B36J28.USD","IE00B4R5TH58.HKD","IE0002141913.USD","LU0109394709.USD","PRAX","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657639346","title":"Earnings Flash (PRAX) Praxis Precision Medicines Posts Q2 Loss $2.87 a Share, vs. FactSet Est of $3.64 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2657639346","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657639346?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:05","pubTimestamp":1786017945,"startTime":"0","endTime":"0","summary":"Earnings Flash (PRAX) Praxis Precision Medicines Posts Q2 Loss $2.87 a Share, vs. FactSet Est of $3.64 Loss","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PRAX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.praxismedicines.com","stockEarnings":[{"period":"1week","weight":-0.0049},{"period":"1month","weight":0.1313},{"period":"3month","weight":0.0305},{"period":"6month","weight":0.0809},{"period":"1year","weight":6.8402},{"period":"ytd","weight":0.2486}],"compareEarnings":[{"period":"1week","weight":-0.002},{"period":"1month","weight":0.0365},{"period":"3month","weight":0.0206},{"period":"6month","weight":0.1111},{"period":"1year","weight":0.1921},{"period":"ytd","weight":0.1232}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase IIb clinical trial for the treatment of essential tremor, as well as in Phase II clinical trial to treat Parkinson's disease; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. Praxis Precision Medicines, Inc. was incorporated in 2015 and is based in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.298328},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.166549},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.160217},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.017086},{"month":5,"riseRate":0.5,"avgChangeRate":-0.087139},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.085881},{"month":7,"riseRate":0.5,"avgChangeRate":0.12656},{"month":8,"riseRate":0.5,"avgChangeRate":0.099782},{"month":9,"riseRate":0.6,"avgChangeRate":0.013557},{"month":10,"riseRate":0.6,"avgChangeRate":0.512334},{"month":11,"riseRate":0.666667,"avgChangeRate":0.073478},{"month":12,"riseRate":0.833333,"avgChangeRate":0.206625}],"exchange":"NASDAQ","name":"Praxis Precision Medicines, Inc.","nameEN":"Praxis Precision Medicines, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Praxis Precision Medicines, Inc.(PRAX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Praxis Precision Medicines, Inc.(PRAX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Praxis Precision Medicines, Inc.,PRAX,Praxis Precision Medicines, Inc.股票,Praxis Precision Medicines, Inc.股票老虎,Praxis Precision Medicines, Inc.股票老虎国际,Praxis Precision Medicines, Inc.行情,Praxis Precision Medicines, Inc.股票行情,Praxis Precision Medicines, Inc.股价,Praxis Precision Medicines, Inc.股市,Praxis Precision Medicines, Inc.股票价格,Praxis Precision Medicines, Inc.股票交易,Praxis Precision Medicines, Inc.股票购买,Praxis Precision Medicines, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Praxis Precision Medicines, Inc.(PRAX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Praxis Precision Medicines, Inc.(PRAX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction